Skystar Bio-Pharmaceutical Co., Ltd Announces Partnership With Tianlong Technology
The Partnership Introduces an Advanced Examination System for Detecting the Avian Bird Flu VirusSkystar Bio-Pharmaceutical (OTC BB: SKBI), a leading Bio-Pharmaceutical Company in China, announced a joint venture with Xi'an Tianlong Science and Technology Limited, who has developed a quick and acc...

Skystar Bio-Pharmaceutical Reports Record Revenue and Income
Income From Continuing Operations Increases 70.5%Skystar Bio-Pharmaceutical (OTC BB: SKBI), a leading Bio-Pharmaceutical Company in China, announced record financial results for the year ended December 31, 2005. Skystar reported a 48.6% increase in total revenue for 2005. Total revenue for ...

Company Expects to Receive Chinese Government's new GMP Certification for its new facility in the Third Quarter
HONG KONG --Skystar Bio-Pharmaceutical (OTC BB: SKBI), a leading Chinese-based developer and producer of veterinary pharmaceutical products, announced today that it expects to complete it's new, state of the art manufacturing facility by the end of September. Skystar also expects to have the new...

Skystar Bio-Pharmaceutical to Develop Avian Influenza (H5N1) Vaccine for People and Animals
Skystar Bio-Pharmaceutical (OTC Bulletin Board: SKBI), a leading Bio-Pharmaceutical Company in China, announced that they expect to develop the high efficient Avian Influenza inactivated vaccine for poultry, birds and people.   The challenge in making an effective Avian Influenza Vaccine...

Skystar Bio-Pharmaceutical's Anti- Avian Influenza Medicine Passes First Phase of Testing
XI'AN, China, Jan. 31 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) ('Skystar', 'Company'), a leading bio-pharmaceutical company in the People's Republic of China ('PRC'), today announced that the Company is raising its guidance for 2007 revenue to ...